Lynch syndrome: A primer for urologists and panel recommendations

Journal of Urology

Volumn 194, Issue 1, 2015, Pages 21-29

  Mork, Maureen ^a   Hubosky, Scott G ^c   Rouprêt, Morgan ^e   Margulis, Vitaly ^b   Raman, Jay ^d   Lotan, Yair ^b   O'Brien, Timothy ^f   You, Nancy ^a   Shariat, Shahrokh F ^g   Matin, Surena F ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^d PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^e ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^f GUY S HOSPITAL   (United Kingdom)

^g MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

carcinoma; colorectal neoplasms; DNA mismatch repair; hereditary nonpolyposis; kidney neoplasms; transitional cell; ureteral neoplasms

Indexed keywords

ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; EPITHELIAL CELL ADHESION MOLECULE; MISMATCH REPAIR PROTEIN PMS2; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6;

BLADDER CANCER; CANCER SCREENING; COLON CANCER; COLON POLYP; COLONOSCOPY; COLORECTAL CANCER; DISEASE ASSOCIATION; GENETIC SCREENING; GERMLINE MUTATION; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SECONDARY PREVENTION; TRANSITIONAL CELL CARCINOMA; TREATMENT RESPONSE; UROLOGIST; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DECISION TREE; UROLOGY;

COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DECISION TREES; HUMANS; PRACTICE GUIDELINES AS TOPIC; UROLOGY;

EID: 84940669443     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2015.02.081     Document Type: Review

References (49)

1. H. Hampel, W.L. Frankel, E. Martin, and et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer) N Engl J Med 352 2005 1851
2. P. Barrow, M. Khan, F. Lalloo, and et al. Systematic review of the impact of registration and screening on colorectal cancer incidence and mortality in familial adenomatous polyposis and Lynch syndrome Br J Surg 100 2013 1719
3. D. Moher, A. Liberati, J. Tetzlaff, and et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement Ann Intern Med 151 2009 264
4. A.K. Win, N.M. Lindor, J.P. Young, and et al. Risks of primary extracolonic cancers following colorectal cancer in Lynch syndrome J Natl Cancer Inst 104 2012 1363
5. R.S. van der Post, L.A. Kiemeney, M.J. Ligtenberg, and et al. Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers J Med Genet 47 2010 464
6. S.C. Skeldon, K. Semotiuk, M. Aronson, and et al. Patients with Lynch syndrome mismatch repair gene mutations are at higher risk for not only upper tract urothelial cancer but also bladder cancer Eur Urol 63 2013 379
7. V.M. Raymond, J.N. Everett, L.V. Furtado, and et al. Adrenocortical carcinoma is a Lynch syndrome-associated cancer J Clin Oncol 31 2013 3012
8. M. Rouprêt, D.R. Yates, E. Comperat, and et al. Upper urinary tract urothelial cell carcinomas and other urological malignancies involved in the hereditary nonpolyposis colorectal cancer (Lynch syndrome) tumor spectrum Eur Urol 54 2008 1226
9. A.H. Gylling, T.T. Nieminen, W.M. Abdel-Rahman, and et al. Differential cancer predisposition in Lynch syndrome: insights from molecular analysis of brain and urinary tract tumors Carcinogenesis 29 2008 1351
10. R.H. Sijmons, L.A. Kiemeney, J.A. Witjes, and et al. Urinary tract cancer and hereditary nonpolyposis colorectal cancer: risks and screening options J Urol 160 1998 466
11. D.G. Crockett, D.G. Wagner, S. Holmäng, and et al. Upper urinary tract carcinoma in Lynch syndrome cases J Urol 185 2011 1627
12. N.M. Lindor, G.M. Petersen, D.W. Hadley, and et al. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review JAMA 296 2006 1507
13. H.T. Lynch, and A. de la Chapelle Hereditary colorectal cancer N Engl J Med 348 2003 919
14. J.R. Jass, and S.M. Stewart Evolution of hereditary non-polyposis colorectal cancer Gut 33 1992 783
15. C.M. Ribic, D.J. Sargent, M.J. Moore, and et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer N Engl J Med 349 2003 247
16. C. Hollande, P. Colin, T. de La Motte Rouge, and et al. Hereditary-like urothelial carcinomas of the upper urinary tract benefit more from adjuvant cisplatin-based chemotherapy after radical nephroureterectomy than do sporadic tumours BJU Int 113 2014 574
17. P. Watson, K.M. Lin, M.A. Rodriguez-Bigas, and et al. Colorectal carcinoma survival among hereditary nonpolyposis colorectal carcinoma family members Cancer 83 1998 259
18. J. Giedl, R. Schneckenpointner, T. Filbeck, and et al. Low frequency of HNPCC-associated microsatellite instability and aberrant MMR protein expression in early-onset bladder cancer Am J Clin Pathol 142 2014 634
19. A. Hartmann, W. Dietmaier, F. Hofstädter, and et al. Urothelial carcinoma of the upper urinary tract: inverted growth pattern is predictive of microsatellite instability Hum Pathol 34 2003 222
20. H.F. Vasen, P. Watson, J.P. Mecklin, and et al. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC Gastroenterology 116 1999 1453
21. A. Umar, C.R. Boland, J.P. Terdiman, and et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability J Natl Cancer Inst 96 2004 261
22. S.G. Hubosky, B.M. Boman, S. Charles, and et al. Ureteroscopic management of upper tract urothelial carcinoma (UTUC) in patients with Lynch Syndrome (hereditary nonpolyposis colorectal cancer syndrome) BJU Int 112 2013 813
23. NCCN Guidelines Genetic/Familial High-Risk Assessment: Colorectal 2014 National Comprehensive Cancer Network Fort Washington, Pennsylvania
24. T. Snowsill, N. Huxley, M. Hoyle, and et al. A systematic review and economic evaluation of diagnostic strategies for Lynch syndrome Health Technol Assess 18 2014 1
25. H.F. Vasen, J.P. Mecklin, P.M. Khan, and et al. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC) Dis Colon Rectum 34 1991 424
26. M.B. Loughrey, P.M. Waring, A. Tan, and et al. Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer Fam Cancer 6 2007 301
27. C.R. Boland, S.N. Thibodeau, S.R. Hamilton, and et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer Cancer Res 58 1998 5248
28. N.M. Lindor, L.J. Burgart, O. Leontovich, and et al. Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors J Clin Oncol 20 2002 1043
29. H. Blaszyk, L. Wang, W. Dietmaier, and et al. Upper tract urothelial carcinoma: a clinicopathologic study including microsatellite instability analysis Mod Pathol 15 2002 790
30. K.M. Ericson, A.P. Isinger, B.L. Isfoss, and et al. Low frequency of defective mismatch repair in a population-based series of upper urothelial carcinoma BMC Cancer 5 2005 23
31. M. Aarnio, M. Säily, M. Juhola, and et al. Uroepithelial and kidney carcinoma in Lynch syndrome Fam Cancer 11 2012 395
32. M. Rouprêt, J. Catto, F. Coulet, and et al. Microsatellite instability as indicator of MSH2 gene mutation in patients with upper urinary tract transitional cell carcinoma J Med Genet 41 2004 e91
33. A.N. Bartley, R. Luthra, D.S. Saraiya, and et al. Identification of cancer patients with Lynch syndrome: clinically significant discordances and problems in tissue-based mismatch repair testing Cancer Prev Res (Phila) 5 2012 320
34. F. Kastrinos, E.W. Steyerberg, R. Mercado, and et al. The PREMM(1,2,6) model predicts risk of MLH1, MSH2, and MSH6 germline mutations based on cancer history Gastroenterology 140 2011 73
35. H.T. Lynch, C.R. Boland, M.A. Rodriguez-Bigas, and et al. Who should be sent for genetic testing in hereditary colorectal cancer syndromes? J Clin Oncol 25 2007 3534
36. F. Audenet, P. Colin, D.R. Yates, and et al. A proportion of hereditary upper urinary tract urothelial carcinomas are misclassified as sporadic according to a multi-institutional database analysis: proposal of patient-specific risk identification tool BJU Int 110 2012 E583
37. M. Rouprêt, M. Babjuk, E. Compérat, and et al. European guidelines on upper tract urothelial carcinomas: 2013 update Eur Urol 63 2013 1059
38. A. Andermann, I. Blancquaert, S. Beauchamp, and et al. Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years Bull World Health Organ 86 2008 317
39. P. Acher, G. Kiela, K. Thomas, and et al. Towards a rational strategy for the surveillance of patients with Lynch syndrome (hereditary non-polyposis colon cancer) for upper tract transitional cell carcinoma BJU Int 106 2010 300
40. I.T. Bernstein, and T. Myrhøj Surveillance for urinary tract cancer in Lynch syndrome Fam Cancer 12 2013 279
41. T. Myrhøj, M.B. Andersen, and I. Bernstein Screening for urinary tract cancer with urine cytology in Lynch syndrome and familial colorectal cancer Fam Cancer 7 2008 303
42. H.F. Vasen, I. Blanco, K. Aktan-Collan, and et al. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts Gut 62 2013 812
43. P. Watson, H.F. Vasen, J.P. Mecklin, and et al. The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome Int J Cancer 123 2008 444
44. R. Davis, J.S. Jones, D.A. Barocas, and et al. Diagnosis, evaluation and follow-up of asymptomatic microhematuria (AMH) in adults: AUA guideline J Urol, suppl 188 2012 2473
45. G.L. Chen, E.A. El-Gabry, and D.H. Bagley Surveillance of upper urinary tract transitional cell carcinoma: the role of ureteroscopy, retrograde pyelography, cytology and urinalysis J Urol 164 2000 1901
46. R.K. Loo, S.F. Lieberman, J.M. Slezak, and et al. Stratifying risk of urinary tract malignant tumors in patients with asymptomatic microscopic hematuria Mayo Clin Proc 88 2013 129
47. R.W. Burt, J.S. Barthel, K.B. Dunn, and et al. NCCN clinical practice guidelines in oncology. Colorectal cancer screening J Natl Compr Canc Netw 8 2010 8
48. A.M. Mills, S. Liou, J.M. Ford, and et al. Lynch syndrome screening should be considered for all patients with newly diagnosed endometrial cancer Am J Surg Pathol 38 2014 1501
49. J. Burn, J. Mathers, and D.T. Bishop Lynch syndrome: history, causes, diagnosis, treatment and prevention (CAPP2 trial) Dig Dis, suppl 30 2012 39